# Codex Conference Review: enrollment_phase2_acceptance

Date: 2026-08-14

## Verdict

**PASS after remediation.** Phase 2 meets its persistence and durable-job acceptance boundary.

## Boundary Compliance

All participants were read-only. No participant modified clinical sources, legacy projects, or Phase 3 product surfaces. Codex performed all accepted repairs and final verification.

## Participant Outputs Reviewed

- CodeBuddy CLI / Kimi 2.6: static `ACCEPT`; tools were unavailable, so it is supporting review rather than the deterministic anchor.
- Pi / Minimax M3: live tests and schema inspection; initially `REVISE`. Its valid findings on deferred-step lease release and 422 field location were repaired.
- Grok Build / Grok 4.6: first full review was `REVISE` and supplied useful defects. The remediation session and same-session recovery both ended `cancelled`; no remediation verdict was counted.

## Conference Panel Review

The panel converged on the idempotency, terminal-event, recovery-progress, SSE and error-classification fixes. It disagreed on stale reopening and direct `rule_set_id` storage; Codex rejected both expansions because they violate immutable source-revision and normalized episode-scope contracts.

## Main-Venue Codex Review

Codex additionally hardened deferred-step selection/release, added natural-Chinese validation field locations, regenerated versioned schemas, and fixed all reproducible defects. Model speculation without a valid product-state reproduction was not accepted.

## Codex Independent Verification

- Backend: `467 passed, 1 skipped, 18 subtests passed`; skip is the pre-existing missing MG-K10-SAR/06003 OCR cache fixture.
- Frontend: `207 passed`; production build passed.
- Browser: `283 passed, 109 configured skips` across 1280/1440/1920/390 viewports.
- Focused anchors include real 8-thread idempotency contention, 8-session atomic event sequences, migration auto-restore, failure terminal SSE, abnormal deferred-state release, and immutable stale-cause behavior.

## Final Decision

Accept and archive Phase 2. Keep the large rearchitecture sequence at Phase 3; do not claim real protocol/OCR/clinical-review completion from this foundation.
